FSD Pharma, Inc., is a publicly traded holding company since May 2018.

FSD BioSciences, Inc., a wholly-owned subsidiary, is a specialty biotech pharmaceutical R&D company focused on developing over time multiple applications of its lead compound, FSD201, ultra-micronized palmitoylethanolamide (PEA). Ultra-micro PEA is known to target the CB2 receptors of the endocannabinoid system of the human body and acts by down-regulating the pro-inflammatory cytokines to effectuate an anti-inflammatory response.

The company has successfully completed Phase 1 first-in-human safety and tolerability study for FSD201 and has found the compound to be safe with no serious adverse side effects. This study also validated considerable scientific literature already published in the European Union that claims safety and tolerability of micro-PEA. Ultra-micro PEA is currently beings dispensed in Italy and Spain as a prescription based medical food supplement since 2004.

The company received permission from the Food and Drug Administration (FDA) on June 1, 2020 to submit an Investigational New Drug Application (IND) for the use of FSD201 to treat COVID-19, the disease caused by the SARS-CoV-2 virus.

Severe COVID-19 is characterized by an over-exuberant inflammatory response that may lead to a cytokine storm and ultimately death. The Company is focused on developing FSD201 for its anti-inflammatory properties to avoid the cytokine storm associated with acute lung injury in hospitalized COVID-19 patients.

Gage Growth Corp. is innovating and curating the highest quality cannabis experiences possible for cannabis consumers in the state of Michigan and bringing internationally renowned brands to market. Through years of progressive industry experience, the firm's founding partners have successfully built and grown operations with federal and state licenses, including cultivation, processing and retail locations. Gage’s portfolio includes city and state approvals for multiple cultivation, processing and provisioning center (dispensaries) locations.

Investor Note: In addition to the 137,789,199 Subordinate Voting Shares that are listed and trading, there are 75,000,000 Subordinate Voting Shares reserved for issuance in connection with the redemption rights attached to Exchangeable Units outstanding. The total number of Subordinate Voting Shares, assuming the redemption of all Exchangeable Units outstanding, is 212,789,199.

Gemina Labs is a biosensor and diagnostic company with a unique and transformative proprietary biochemistry that significantly improves the performance of human and animal testings, including COVID-19, Influenza and other viruses.

Vodis Pharmaceuticals Inc. is a craft cannabis producer in Delta, British Columbia, Canada.  The company was issued a Standard Cultivation licence and Standard Processing licence under the Cannabis Act on January 31, 2020.  The company operates a 12,000 sqft indoor facility growing proprietary cultivars for the adult-use, recreational cannabis market.  At full capacity, the Delta facility will yield approximately 1,500 kg of craft cannabis annually.